Pallas Health vs Vaylen: Compare pricing, formats, and policies
Pallas Health vs Vaylen: both are cash-pay telehealth options for GLP-1 care, but Pallas offers clinician choice of brand-name or compounded medication while Vaylen publishes very low prepaid 12-month rates. Early verdict: choose Pallas if you want access to FDA-approved pens plus a compounded fallback and clinician-determined route; choose Vaylen if you want the lowest effective monthly rate on a prepaid plan and a needle-free oral option.
Direct comparison at a glance: core differences
Pallas Health and Vaylen both sell clinician-supervised weight-loss plans, but they differ in three main areas: medication pathways, pricing structure, and prepay versus post-review workflows. Each provider states that compounded medications are not FDA-approved, and both platform disclosures say eligibility is determined by a US-licensed clinician.
1. Medication options and clinician choice
Pallas Health: clinician reviews your health history and personalizes the plan, offering FDA-approved Wegovy, Ozempic, Zepbound and Mounjaro, or compounded semaglutide and tirzepatide when a brand medication is not the right fit. Pallas says both routes come from one intake, so a clinician can pick brand-name pen or a per-patient compounded preparation.
Vaylen: offers compounded semaglutide injectable, oral semaglutide tablets, and tirzepatide injectable on one platform. Vaylen highlights a needle-free oral tablet option and the ability for a clinician to switch molecules or format without changing providers. Unlike Pallas, Vaylen does not offer branded pens; all medications it markets are compounded.
2. Pricing and billing models
Pallas lists compounded semaglutide at $139 for the first month, then $597 every 12 weeks, which Pallas calculates as a $199/mo average. Compounded tirzepatide is $179 first month, then $897 every 12 weeks ($299/mo average). Brand-name pens are cash-pay with monthly figures published per product. Pallas says its compounded plans are priced by medication rather than by milligram, so titrating up does not raise the plan price.
Vaylen publishes annualized prepaid 12-month rates: semaglutide injectable from $83.25/mo on the 12-month program or $224/mo month to month; oral semaglutide $99/mo on the 12-month program or $249/mo monthly; tirzepatide $149/mo on the 12-month program or $299/mo monthly. Vaylen emphasizes that every 12-month rate is billed upfront in a single charge and that the clinician review follows payment, with a full refund if declined.
Check Pallas pricing and options
3. Evaluation flow, refunds, and timing
Pallas positions clinician review before treatment and refunds the first payment in full if a clinician decides treatment is not right for you. Pallas also notes that a video visit is required in seven states plus Washington, D.C., while most states are asynchronous (43 of 50 need no video visit).
Vaylen requires prepayment for the annual plan before a clinician reviews the file. Vaylen states a full refund for that billing cycle if the clinician declines to prescribe. Vaylen touts clinician review within 24 hours and free discreet shipping in 1 to 3 business days. Pallas notes free expedited shipping but emphasizes compounded plans renew every 12 weeks rather than monthly.
4. Shipping, availability, and care access
Pallas: free expedited and discreet shipping, compounded in the USA, care-team messaging and provider care included in the plan price, weekday care-team hours 9 AM to 5 PM ET, and no emergency services. Pallas is cash-pay only and does not bill insurance; FSA/HSA use may require a Letter of Medical Necessity.
Vaylen: free discreet shipping in 1 to 3 business days, licensed clinicians via OpenLoop Health, claims availability in all 50 states, HIPAA protection, and 24/7 care-team messaging included. Vaylen also notes cancel anytime and a published refund if the clinician declines in that cycle. Vaylen warns that prepaid terms for unused portions of a year are not published.
Concise comparison table
| Criteria | Pallas Health | Vaylen |
|---|---|---|
| Medication formats | Brand-name pens and compounded semaglutide or tirzepatide | Compounded injectable semaglutide, oral semaglutide tablet, and tirzepatide |
| Starting price (compounded) | Compounded semaglutide $139 first month, then $199/mo avg | Semaglutide from $83.25/mo on 12-month plan |
| Pricing model | First month intro price; plans renew every 12 weeks for compounded meds | Annualized prepaid 12-month rates billed upfront or higher month-to-month |
| Refund if clinician declines | Refunded in full if clinician decides treatment is not right | Full refund for that billing cycle if clinician declines |
| States and visits | 100% online; asynchronous in most states; video visit required in 7 states plus D.C. | Licensed in 50 states; clinician review within 24 hours |
| Shipping | Free expedited, discreet shipping from US-licensed pharmacies | Free discreet shipping in 1 to 3 business days |
| Regulatory note | Compounded medications are not FDA-approved | Compounded medications are not FDA-approved |
Other notable points
Pallas highlights clinician choice between branded FDA-approved pens and compounded options prepared by US-licensed compounding pharmacies and discloses that compounded meds are not FDA-approved. Vaylen emphasizes low prepaid rates, a needle-free oral tablet option, and that payment precedes clinician review with a published refund if not approved.
Final guidance: Choose based on these supported differences
Choose Pallas Health if you want a clinician to pick between brand-name pens and a compounded preparation, a one all-in plan price that includes provider care and messaging, and compounded plans priced by medication rather than by milligram. Choose Vaylen if you want the lowest effective monthly rate on a prepaid 12-month semaglutide program, prefer a needle-free oral semaglutide option, and accept paying upfront before clinician review with a published refund if declined.